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Background/objective: An inflammation of the cutis and subcutis of the external auditory 
canal is a primary symptom in cases of acute otitis externa. It is usually treated locally, since this 
type of therapy ensures a high concentration of the drug and interacts at the site of inflammation 
with no systemic effects. This systematic review compares the efficacy of treatment using a 
ciprofloxacin 0.2% solution with other therapeutic options.
Methods: After compiling a catalog of search terms, medical databases were searched systemati­
cally for randomized, controlled studies. This search initially yielded a total of 38 studies which 
were then evaluated by three independent reviewers. The number of studies was subsequently 
reduced to 14: six studies using a ciprofloxacin 0.2% solution, and eight studies using both 
0.2% and 0.3% solutions.
Results: The studies included in the review demonstrate the statistical equivalence between the 
ciprofloxacin solution (0.2%) and the reference products PNH (a combination of polymyxin B, 
neomycin sulfate and hydrocortisone), auriculum powder, and a ciprofloxacin foam with respect 
to the cure rate. The research groups consistently observed high in vitro activity of ciprofloxacin 
against Pseudomonas aeruginosa.
Conclusion: This systematic review confirms the hypothesis of ciprofloxacin’s noninferiority 
in the treatment of otitis externa, in terms of the cure rate and microbiological eradication.
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Introduction
Otitis externa
Inflammation of the cutis and subcutis of the external auditory canal is a primary 
symptom in acute otitis externa. An affected pinna can be a secondary symptom. 
  Occasionally, the eardrum can also be inflamed.1 Inflammation of the ear can occur in 
an acute and a chronic form. In some cases, the clinical picture develops to a necrotizing 
stage. Statistically, one in ten people suffers at least once in his life from otitis externa. 
In 10% of cases, the inflammation is bilateral.2 Currently, many different therapies are 
applied to ease the symptoms. The purpose of this review is to compare the efficacy 
of ciprofloxacin 0.2% antibiotic ear solution with other treatment options.
General etiology
An intact auditory canal possesses the ability to cleanse itself by migrating the sloughed 
epithelia cells outwards with cerumen. The main function of cerumen is to protect the 
membrane that lines the auditory canal against inflammation. Cerumen maintains the 
soft consistency of the membrane and also ensures water resistance. Whether it also Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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has an antimicrobial effect has not yet been clarified. If the 
cerumen is pushed from the outer part of the auditory canal 
toward the eardrum using a cotton swab, its effectiveness is 
lowered. Should bacteria then enter the ear canal, the risk 
of progressive bacterial growth increases. This can occur 
particularly in swimming pools, which is why the term 
“swimmer’s ear” is commonly used.3
Likewise, congenital or acquired anatomical anomalies 
(eg, narrow passages), the use of hearing aids, or the 
aforementioned radical ear and ear canal hygiene with the 
complete removal of cerumen or drainage can destabilize 
the sensitive environment and thus predispose the external 
auditory canal to inflammation.1
Pathogens
The pH of the external auditory canal varies between 5.0 and 
5.7 and is therefore slightly acidic. Such conditions inhibit 
bacterial growth.1 In 1981, Brook examined the physiological, 
normal flora of the external auditory canal in pediatric 
patients. In descending order of concentration, colonization 
with aerobes such as Staphylococcus epidermidis, diphthe­
roid species, and a­hemolyzing streptococci as well as 
anaerobes such as propionibacterium acnes, was observed. 
Pseudomonas aeruginosa and Staphylococcus aureus act 
pathogenically against such flora and are cited in the technical 
literature as the main causative organisms. Sporadically, 
viruses and fungi can also cause otitis externa.1,4
Clinical picture
Bacterial otitis externa in its mild form can be accompanied 
by only minor pain and subdued swelling. In its severe form, 
however, the symptoms are associated with excruciating pain, 
otorrhea, and the complete closure of the external auditory 
canal. The result is conductive deafness.1
Apart from the typical acute form of otitis externa, 
  special forms can appear such as otitis externa circumscripta, 
which emanates from a hair follicle inflammation, or otitis 
externa necroticans (“maligna”), which can take a fulminant 
course and therefore requires maximum, usually intravenous 
treatment.1,5
In the majority of published clinical studies on the 
treatment of otitis externa, pain, swelling, otorrhea, and 
redness are evaluated as typical parameters for rating the 
clinical signs.
Therapy
Otitis externa is usually treated locally.1 Ototoxic antibiotics 
such as aminoglycosides should not be applied in patients 
with a perforated tympanic membrane. If an antibiogram 
has been made, the optimum antibiotic otologic drug can be 
determined. If none is available, “calculated antibiosis” is 
recommended, ie, a drug is used that is effective against the 
two most common pathogens S. aureus and P . aeruginosa.6 
Individual decisions must be made in case of resistance. 
Often, an antiseptic ingredient such as aluminium acetate/
acetic acid is added to the antibiotic. Due to their acidic 
properties, these substances are especially suitable for 
lowering the pH value in the auditory canal, so that the 
main pathogens P . aeruginosa and S. aureus, which reach 
their optimal pH between 6.5 and 7.3, do not obtain perfect 
growing conditions or, in an ideal case, are killed.1,7
For years, glucosteroids had the reputation of primarily 
reducing the swelling of the auditory canal. Newer studies, 
however, also ascribe to them antibacterial and antifungal 
effects in otitis externa. Yet the number of available studies 
on steroidal monotherapies is still rather low.5
Nonsteroidal anti­inflammatory drugs should also be 
administered for pain relief.1
Ciprofloxacin
Ciprofloxacin is a synthetic antibiotic with a broad spectrum 
of activity and has the chemical formula C17H18FN3O3. 
Belonging to the group of fluoroquinolones (gyrase 
inhibitors), it acts as a bactericide particularly against 
gram­negative pathogens by inhibiting DNA replication 
(topoisomerase II) and interfering in the enzymatic 
activity of topoisomerase IV, both of which are required 
for the bacteria’s cell division, transcription, repair, and 
recombination. It is moderately effective against gram­
positive pathogens, while it shows no relevant activity 
against fungi or parasites.8
In 75% of cases, ciprofloxacin is eliminated unchanged by 
renal excretion. It is also metabolized through the liver and 
eliminated through bile and is thus subject to   enterohepatic 
circulation.8 Ciprofloxacin ranks among the most effective 
fluoroquinolones against P . aeruginosa and can also show 
very high in vitro activity against enterobacteria and 
  Haemophilus influenzae. Being the only antibiotic available 
for oral treatment of infections caused by P . aeruginosa, it 
is administered in particular to treat chronic purulent otitis 
media, and can be applied locally and systemically to treat 
acute otitis externa.9
Ciprofloxacin constitutes the drug of choice for treating 
severe otitis externa in children and adolescents as it has 
been the subject of extensive investigation and is available 
in syrup form.10Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Besides its systemic effect, ciprofloxacin is used more 
often topically for its local effects in the form of eye or ear 
drops. This fluoroquinolone thereby possesses a very broad 
spectrum of indications which range from complicated uri­
nary tract infections, infections of the respiratory system, 
skin and bones, to severe typhoid salmonella infections, or 
bacterial conjunctivitis. Known side effects include gastro­
intestinal complaints (nausea, diarrhea, dyspepsia), disorders 
of the central nervous system (headache, nervousness/rest­
lessness, dizziness, tremor, hyposmia), and skin irritations 
and eosinophilia.11
The undesirable effects of systemic treatment can be 
largely avoided through topical administration, however. 
A high local concentration is in fact attained, yet resorption 
does not occur. Therefore, itching or burning at the applica­
tion site or superinfections of the ear can arise due to robust 
pathogens. Allergic reactions occur very rarely.10 Systemic 
side effects of local application occasionally include dizzi­
ness and headache.
Materials and methods
Search methods used to identify studies
The electronic databases Cochrane Ear, Nose and Throat Dis­
orders Group Trials Register, The Cochrane Central Register 
of Controlled Trials (CENTRAL), PubMed, MEDLINE, 
EMBASE, and Web of Science were systematically searched 
for randomized, controlled studies. Using MeSH, a search 
term catalog was compiled with the following terms that 
were then entered in combinations: external ear, inflam-
mation of the external ear, acute otitis externa, quinolone, 
ciprofloxacin 0.2%, ciprofloxacin, solution, ear drops, drug 
therapy, anti-bacterial agents, antifungal, antibiotics.
Restrictions with respect to language, publication date, or 
publication status were not initially made. This review was 
also limited to published work. The last search was started 
on 1 March 2011.
Patients
Patients (both children and adults) with the diagnosis of acute 
otitis externa were included in the review. Not included were 
patients who suffered from a chronic form of external otitis 
or otitis media.
Parameters
Symptom improvement and microbiological eradication 
were defined as primary outcome parameters. Time to com­
plete disappearance of symptoms and any side effects were 
observed as further aspects.
Results
Search results
Thirty­eight studies satisfied our search criteria, and we 
examined the abstracts of these. When this process was 
completed, the number of suitable studies decreased to 36; 
we then worked through their full texts (Figure 1). After three 
reviewers came to a consensus concerning further elimina­
tions, six and eight studies, respectively, were available for 
this systematic review (Table 1).12–19
We were denied access to the full text of two of these eight 
randomized controlled trials. The comprehensive publication 
by Lildholdt et al15 and the text by Psifidis et al18 could not be 
requested, which is why detailed data are missing.
Unpublished studies were not considered in this systematic 
review.
Background (included studies)
Treatment doses
Besides six studies that investigated a 0.2% ciprofloxacin 
drug, we also included two more studies that used a 0.3% 
ciprofloxacin product (Table 2).14,16
The ciprofloxacin dose of the ear solutions used in the 
individual studies was comparable. The majority planned a 
7­day application phase, during which the study participants 
applied three drops to each ear twice daily. Marom et al16 
raised the dose to four drops (0.3% ciprofloxacin), and 
  Goldenberg et al14 doubled the application period to 2 weeks. 
The exact dose remains unclear in the study by Drehobl et al13 
in which the study period was also 7 days, with applications 
twice daily, but the study specified the dose as ampoule 
(“vial”) rather than stating the number of drops.
Outcomes assessed
Clinical response
Clinical success was, in part, classified differently and 
measured at various points in times (Table 2). In addition, 
the definition of treatment success varied slightly among 
the studies. Some studies defined clinical success as 
complete recovery (resolution) with complete freedom 
from symptoms. In others, it included mild symptoms, but 
a distinct improvement from the initial value. In principle, 
the symptoms and signs typical for the disease and used in 
the evaluation were similar. They included edemas, pain, or 
hypersensitivity of the ear, and otorrhea.
Time to recovery – time to end of pain
Time to end of pain constituted a relevant target value for 
three of the studies included:15,17,19 Pistorius et al17 determined Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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a
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h
e
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e
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0
 
d
a
y
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u
s
e
 
 
o
f
 
t
o
p
i
c
a
l
 
o
r
 
s
y
s
t
e
m
i
c
 
a
n
t
i
b
i
o
t
i
c
s
 
i
n
 
t
h
e
 
p
r
e
c
e
d
i
n
g
 
 
7
 
d
a
y
s
;
 
u
s
e
 
o
f
 
a
n
y
 
m
e
d
i
c
a
t
i
o
n
 
f
o
r
 
t
r
e
a
t
m
e
n
t
 
o
f
 
o
t
i
t
i
s
 
e
x
t
e
r
n
a
 
o
r
 
o
t
i
t
i
s
 
m
e
d
i
a
 
i
n
 
t
h
e
 
p
r
e
c
e
d
i
n
g
 
3
6
 
h
o
u
r
s
;
 
s
e
b
o
r
r
h
e
i
c
 
d
e
r
m
a
t
i
t
i
s
 
o
f
 
t
h
e
 
e
x
t
e
r
n
a
l
 
a
u
d
i
t
o
r
y
 
c
a
n
a
l
;
 
c
h
r
o
n
i
c
 
o
t
i
t
i
s
 
e
x
t
e
r
n
a
 
o
r
 
o
t
o
r
r
h
e
a
 
o
f
 
3
 
w
e
e
k
s
’
 
d
u
r
a
t
i
o
n
;
 
k
n
o
w
n
 
f
u
n
g
a
l
 
i
n
f
e
c
t
i
o
n
 
o
f
 
t
h
e
 
e
a
r
;
 
m
a
s
t
o
i
d
 
d
i
s
e
a
s
e
 
o
r
 
m
a
s
t
o
i
d
 
s
u
r
g
e
r
y
 
(
w
i
t
h
i
n
 
6
0
 
d
a
y
s
 
o
f
 
s
t
u
d
y
 
e
n
t
r
y
)
;
 
t
y
m
p
a
n
o
s
t
o
m
y
 
t
u
b
e
s
 
c
u
r
r
e
n
t
l
y
 
i
n
 
p
l
a
c
e
 
o
r
 
r
e
m
o
v
e
d
 
w
i
t
h
i
n
 
3
 
m
o
n
t
h
s
 
o
f
s
t
u
d
y
 
e
n
t
r
y
;
 
k
n
o
w
n
 
p
e
r
f
o
r
a
t
i
o
n
 
o
f
 
t
h
e
 
e
a
r
d
r
u
m
 
o
r
 
p
e
r
f
o
r
a
t
i
o
n
 
w
i
t
h
i
n
 
6
 
m
o
n
t
h
s
 
o
f
 
s
t
u
d
y
 
e
n
t
r
y
;
 
k
n
o
w
n
 
s
i
g
n
i
fi
c
a
n
t
 
u
n
d
e
r
l
y
i
n
g
 
d
i
s
e
a
s
e
,
 
i
n
c
l
u
d
i
n
g
 
d
i
a
b
e
t
e
s
 
m
e
l
l
i
t
u
s
,
 
h
u
m
a
n
 
i
m
m
u
n
o
d
e
fi
c
i
e
n
c
y
 
v
i
r
u
s
 
i
n
f
e
c
t
i
o
n
 
o
r
 
o
t
h
e
r
 
i
m
m
u
n
o
c
o
m
p
r
o
m
i
s
e
d
 
c
o
n
d
i
t
i
o
n
s
;
 
k
n
o
w
n
 
h
y
p
e
r
s
e
n
s
i
t
i
v
i
t
y
 
t
o
 
a
n
y
 
c
o
m
p
o
n
e
n
t
 
o
f
 
t
h
e
 
s
t
u
d
y
 
m
e
d
i
c
a
t
i
o
n
s
;
 
p
r
e
g
n
a
n
c
y
 
o
r
 
l
a
c
t
a
t
i
o
n
;
 
p
r
e
v
i
o
u
s
 
e
n
r
o
l
m
e
n
t
 
i
n
 
t
h
i
s
 
s
t
u
d
y
;
 
o
r
 
a
n
y
 
o
t
h
e
r
 
c
o
n
d
i
t
i
o
n
 
t
h
a
t
 
m
i
g
h
t
 
i
n
t
e
r
f
e
r
e
 
w
i
t
h
 
p
a
r
t
i
c
i
p
a
t
i
o
n
 
i
n
 
t
h
e
 
s
t
u
d
y
.
L
i
l
d
h
o
l
d
t
 
 
e
t
 
a
l
1
5
e
q
u
i
v
a
l
e
n
c
e
 
 
s
t
u
d
y
N
o
 
b
l
i
n
d
i
n
g
3
-
a
r
m
 
s
t
u
d
y
;
 
 
G
r
o
u
p
 
A
:
 
c
i
p
r
o
fl
o
x
a
c
i
n
 
 
G
r
o
u
p
 
B
:
 
c
i
p
r
o
fl
o
x
a
c
i
n
 
+
 
h
y
d
r
o
c
o
r
t
i
s
o
n
e
 
 
G
r
o
u
p
 
C
:
 
P
N
H
8
3
8
P
a
t
i
e
n
t
s
 
w
i
t
h
 
c
l
i
n
i
c
a
l
 
s
i
g
n
s
 
a
n
d
 
 
s
y
m
p
t
o
m
s
 
o
f
 
a
c
u
t
e
,
 
 
d
i
f
f
u
s
e
 
e
x
t
e
r
n
a
l
 
o
t
i
t
i
s
P
s
i
fi
d
i
s
 
 
e
t
 
a
l
1
8
e
q
u
i
v
a
l
e
n
c
e
 
 
s
t
u
d
y
N
o
 
b
l
i
n
d
i
n
g
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-
a
r
m
 
s
t
u
d
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r
o
u
p
 
A
:
 
P
N
H
 
 
G
r
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u
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c
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p
r
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fl
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h
y
d
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o
n
e
 
 
G
r
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u
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c
i
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c
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n
9
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p
 
A
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3
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o
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2
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r
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0
P
a
t
i
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r
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i
e
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A
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g
o
l
o
g
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s
i
g
n
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d
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d
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n
s
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P
r
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r
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a
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i
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p
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i
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r
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e
t
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O
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c
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c
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p
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c
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b
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a
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b
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f
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p
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c
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t
h
e
r
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e
r
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o
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i
c
a
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d
i
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e
r
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o
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h
e
 
e
A
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c
o
n
g
e
n
i
t
a
l
 
a
b
n
o
r
m
a
l
i
t
i
e
s
 
o
f
 
t
h
e
 
e
A
C
 
o
r
 
o
b
s
t
r
u
c
t
i
v
e
 
b
o
n
y
 
e
x
o
s
t
o
s
i
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m
a
s
t
o
i
d
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o
r
 
o
t
h
e
r
 
s
u
p
p
u
r
a
t
i
v
e
 
n
o
n
i
n
f
e
c
t
i
o
u
s
 
e
a
r
 
d
i
s
o
r
d
e
r
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p
r
e
s
e
n
c
e
 
o
f
 
m
i
d
d
l
e
 
e
a
r
 
e
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u
s
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o
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o
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n
d
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n
g
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c
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a
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b
s
c
e
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o
l
y
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o
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g
r
a
n
u
l
a
t
i
o
n
 
t
i
s
s
u
e
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a
n
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s
e
r
i
o
u
s
 
u
n
d
e
r
l
y
i
n
g
 
d
i
s
e
a
s
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p
r
e
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A
O
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3
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a
y
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b
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r
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e
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b
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D
a
t
a
 
w
e
r
e
 
c
o
l
l
e
c
t
e
d
 
o
n
 
a
g
e
,
 
g
e
n
d
e
r
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a
n
d
 
m
e
d
i
c
a
l
 
a
n
d
 
s
u
r
g
i
c
a
l
 
h
i
s
t
o
r
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A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
O
e
,
 
a
c
u
t
e
 
o
t
i
s
 
e
x
t
e
r
n
a
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e
A
C
,
 
e
x
t
e
r
n
a
l
 
a
u
d
i
t
o
r
y
 
c
a
n
a
l
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C
S
O
M
,
 
c
h
r
o
n
i
c
 
s
u
p
p
u
r
a
t
i
v
e
 
o
t
i
t
i
s
 
m
e
d
i
a
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Table 2 Study design (included studies)
Study ID Medications Duration and dose Primary endpoint Secondary parameters Safety
Pistorius  
et al17
Group A:  
Ciprofloxacin otic drops  
as hydrochloride  
monohydrate (0.2%)  
Group B:  
Ciprofloxacin otic drops  
as hydrochloride  
monohydrate (0.2%) plus  
hydrocortisone (0.1%)  
Group C:  
combination of  
Polymyxin B (10.000 U),  
neomycin sulfate (3.5 mg/mL)  
and hydrocortisone (0.1%)
7 days  
Group A:  
3 drops twice daily  
Group B:  
3 drops twice daily  
Group C:  
3 drops 3 times a day  
(,13 years of age)  
or 4 drops  
(.13 years of age)
Clinical success 
(resolution or 
improvement of 
symptoms) at the  
end of therapy  
(Day 10–17)
Antimicrobial effectiveness 
(microbiological  
eradication) at the end  
of therapy (Day 10–17)  
Time until ear pain 
disappeared completely  
via visual analog scale
Medication-
related adverse 
events
Arnes and  
Dibb12
Group A:  
Ciprofloxacin (0.2%)  
as ear drops  
Group B:  
drops containing  
oxytetracycline (5 mg/mL) 
polymyxin B (10,000 units/mL)  
and hydrocortisone (15 mg/mL)
7 days  
Group A:  
2–3 drops twice daily 
Group B:  
2–3 drops twice daily
Clinical success 
(complete resolution, 
marked improvement, 
slight improvement, 
failure, or  
indeterminate)  
at the end of  
therapy (Day 8)
Bacteriological assessment 
(eradication, persistence, 
recurrence, superinfection)  
individual (investigator’s) 
assessment (completely 
successful, partially  
successful, unsuccessful, 
indeterminate)
Clinical side 
effects (adverse 
events)
Roland  
et al19
Group A:  
Otic solution consisting  
of ciprofloxacin and  
hydrocortisone  
Group B:  
Combination of PNH  
(polymyxin B/neomycin/
hydrocortisone)  
plus the antibiotic  
amoxicillin
Group A:  
7 days,  
3 drops twice daily  
Group B:  
10 days,  
2 drops 3 times a day  
(,17 years of age)  
or 4 drops 3 times a day 
(.17 years of age)
Clinical success/ 
response to therapy 
(resolution) after 
treatment ended  
(Group A: Day 8,  
Group B: Day 11)
Microbiological eradication 
after treatment ended 
(percentage of patients  
with resolution of  
disease-specific infection)  
Time to end of pain  
Symptom severity  
(4-point scale for otalgia  
and tenderness)
Adverse events 
or serious 
adverse events
Drehobl  
et al13
Group A:  
Cetraxal (ciprofloxacin otic 
solution 0.2%)  
Group B:  
PNH otic solution;  
neomycin sulfate  
(3.5 mg/mL neomycin base),  
polymyxin B (10 000 U)  
and hydrocortisone (1%)
7 days  
Group A:  
1 vial twice daily  
(morning and evening) 
Group B:  
4 drops 3 times daily  
(for patients .13 years  
of age) or 3 drops  
(for patients ,13 years  
of age) (morning,  
afternoon, evening)
Clinical success 
(proportion of  
patients with clinical 
cure) after follow-up  
period (day 15–17).  
Clinical cure was  
defined as a score  
of 0 for otalgia,  
edema, and otorrhea
Clinical success  
(proportion of patients  
with clinical cure) at the  
end of treatment (Day 8–10)  
Clinical improvement  
(defined as a score of 0 
or 1 for otalgia, edema, 
and otorrhea), resolution 
of otalgia, and clinical + 
microbiologic cure at the  
end of treatment and after  
the follow-up period
Drug-related 
adverse events
Lildholdt  
et al15
Group A:  
Ciprofloxacin (0.2%)  
otic solution  
Group B:  
Combination of  
ciprofloxacin (0.2%)  
otic solution and  
hydrocortisone (0.1%)  
Group C:  
Suspension of polymyxin 
B-neomycin sulfate  
(3.5 mg/mL)- 
hydrocortisone (1%)
7 days  
Group A:  
3 drops twice daily  
Group B:  
3 drops twice daily  
Group C:  
4 drops 3 times a day
Clinical success 
(resolution or 
improvement) 
maintained at  
follow-up about  
3 weeks later
Median time to end  
of ear pain  
evaluation of ear cultures
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this parameter via the Visual Analog Scale; Lildholdt et al15 
and Roland et al19 rated pain perception in diary entries on 
a scale of 0–4.
Goldenberg et al14 evaluated pain intensity at two set 
times: Day 3–4 and Day 14.
An alternative approach to analyzing pain was chosen 
by Marom et al16 who, instead of the time to end of pain, 
evaluated the basic development of pain perception based 
on daily entries via the visual analog scale.
Microbiological response
With the exception of one study, the microbiological 
effectiveness of the study medication, among others, was 
measured as the secondary outcome measure.16
Upon inclusion of the patients, samples were taken to 
determine the causative organisms. This procedure was 
repeated at the end of treatment (or alternatively after a 
follow­up period). The classification scheme was defined 
differently in the individual studies:
Drehobl et al13 divided the samples into “no exudates 
observed”, “exudate was present, but there was no growth on 
culture”, “exudate was present, and culture showed some patho­
gen growth at baseline or patient’s response was clinical failure”, 
or “exudate was present, and culture showed one or more new 
pathogens” and assessed them at the end of treatment and also 
after a follow­up period. Patients who tested positive for bacteria 
at the beginning of the study and then tested negative later during 
the study came into the category “microbial cure.”
Table 2 (Continued)
Study ID Medications Duration and dose Primary endpoint Secondary parameters Safety
Psifidis  
et al18
Group A:  
Combination of  
polymyxin B (10,000 U/mL),  
neomycin (3.5 mg/mL),  
and hydrocortisone  
(10 mg/mL)  
Group B:  
Combination of 0.2% 
ciprofloxacin (2 mg/mL) and  
hydrocortisone (10 mg/mL)  
Group C:  
Ciprofloxacin (0.2%) alone
7 days  
Group A:  
3 drops 3 times daily  
Group B:  
3 drops twice daily  
Group C:  
3 drops twice daily
Clinical success 
(complete  
resolution of  
external otitis)  
at the end of the  
follow-up period  
(Day 21–35)
Microbiological  
effectiveness (eradication, 
persistence, superinfection)
Adverse events
Goldenberg  
et al14
Group A:  
Auricularum powder 
(dexamethasone  
10 mg, oxytetracycline  
HCl 90,000 U, polymyxin B 
sulfate 100,000 U, nystatin  
1,000,000 U; Trima, Serolam 
Laboratories, Germany)  
Group B:  
Ciprofloxacin 0.3%  
(Ciloxan, Alcon Laboratories, 
 Fort worth, TX)  
Group C: Tobramycin  
(Tobrex, Alcon Laboratories)
14 days  
Group A:  
1 application  
twice daily  
Group B:  
3 times a day  
Group C:  
3 times a day
Clinical success  
(rate of cure) at  
Day 3–4 after  
initial treatment
Clinical success  
(rate of cure) at  
Day 14  
Microbiological  
effectiveness
Adverse events
Marom  
et al16
Group A:  
Foam Otic Cipro, 0.3% 
ciprofloxacin  
foam-based formulation  
Group B:  
Ciloxan, 0.3%  
solution-based ciprofloxacin
7 days  
Group A:  
One application  
twice daily  
Group B:  
4 drops twice daily
Clinical response/ 
cure defined as 
resolution (absence 
of AOe-related signs 
and symptoms) or 
improvement  
(presence of AOe-
related minor signs 
or symptoms, with 
no further therapy 
required) at the end  
of therapy (Day 8–14)
Otorrhea cessation  
Pain relief
Adverse events
Abbreviation: AOe, acute otis externa.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 3 Results
Study ID Clinical response Time to  
end of pain
Microbiological response
Definition Numbers Bacteriological  
assessment
Effectiveness
Pistorius et al17 Clinical resolution  
or improvement
Group A: 93%  
Group B: 90%  
Group C: 87%
Group A: 4.7 days  
Group B: 3.8 days  
Group C: 4.1 days
Pseudomonas  
aeruginosa: 67%
Bacteriological  
eradication  
(including presumed  
eradication)  
Group A: 92%  
Group B: 95%  
Group C: 87%
Arnes and Dibb12 Complete success,  
partial success,  
unsuccessful,  
indeterminate
Complete success  
Group A: 14 (87.5%)  
Group B: 5 (35.7%)  
Partial success  
Group A: 2 (12.5%)  
Group B: 4 (28.6%)  
Unsuccessful or 
indeterminate  
Group A: 0  
Group B: 5 (35.7%)
  P. aeruginosa  
Group A: 6 (37.5%)  
Group B: 7 (50%)
eradication  
Group A: 15 (93.75%)   
Group B: 7 (50%)  
Persistence  
Group A: 1 (6.25%)  
Group B: 7 (50%)  
Superinfection  
Group A: 1 (6.25%)  
Group B: 0
Roland et al19 Cured or  
improved  
7 days after  
treatment ended
Group A: 94.3%  
Group B: 89.8%
Group A: 6 days  
Group B: 6 days
  eradication  
Group A: 67 (95.7%)  
Group B: 53 (89.8%)  
Superinfection  
Group A: 1 (1.4%)  
Group B: 2 (3.4%)  
Failure  
Group A: 2 (2.9%)  
Group B: 4 (6.8%)
Drehobl et al13 Clinical cure of  
otitis symptoms  
after follow-up  
(score 0 for  
otalgia, edema,  
and otorrhea)
Group A. 86.6%  
Group B: 81.1%
    P. aeruginosa  
Group A: 87.5%  
Group B: 78.6%  
Staphylococcus aureus  
Group A: 72.7%  
Group B: 75.9%
Lildholdt et al15 Resolution or  
improvement 
after follow- 
up period  
(3 weeks later)
Group A: ∼95%  
Group B: ∼95%
Median: 4.8 days  
(no statistically  
significant difference)
P. aeruginosa: 64% Persisting P. aeruginosa   
Group A: 9 (8.7%)  
Group B: 11 (9.4%)  
Group C: 22 (21.4%)
Psifidis et al18 Complete resolution  
of external otitis
Group A: 84.4%  
Group B: 100%  
Group C: 96.7%
  P, aeruginosa  
Group A: 18 (56.3%)  
Group B: 13 (44.8%)  
Group C: 11 (36.7%)
eradication  
Group A: 72%  
Group B: 83.3%  
Group C: 93.8%  
Persistence  
Group A: 12%  
Group B: 5.6%  
Group C: 6.3%  
Superinfection  
Group A: 16%  
Group B: 11.1%  
Group C: 0%
Goldenberg et al14 Cured at day  
3–4 after 
 initial treatment
Group A: 86%  
Group B: 77%  
Group C: 56%
P.: 86 (72%)  
S. aureus: 22 (18%)  
Proteus mirabilis: 6 (5%)  
Coagulase-negative  
Staphylococcus: 6 (5%)
P. aeruginosa  
Group A: 0   
Group B: 0  
Group C: 10%  
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Table 3 (Continued)
Study ID Clinical response Time to  
end of pain
Microbiological response
Definition Numbers Bacteriological  
assessment
Effectiveness
S. aureus  
Group A: 0  
Group B: 2.5%  
Group C: 0  
Staphylococcus 
coagulase-negative  
Group A: 0  
Group B: 5%  
Group C: 10%
Marom et al16 Resolution (absence  
of signs and symptoms)  
or improvement (presence  
of symptoms with no  
further therapy required)
1)   PP population  
Resolution  
Group A: 25 (86.2%)  
Group B: 22 (78.6%)  
improvement  
Group A: 4 (13.8%)  
Group B: 6 (21.4%) 
2)   iTT population  
Resolution + 
improvement  
Group A: 93.6%  
Group B: 93.8%
     
Abbreviations: iTT, intention-to-treat; PP; per-protocol.
Arnes et al12 Pistorius et al17, and Psifidis et al18 defined 
outcome critaria from “eradication” to “superinfection” or 
“reinfection” and examined the microbiological activity at 
the end of treatment and after follow­up. The change or the 
reduction of pathogenic infections could be determined in 
this way for each group and each pathogen.
In contrast, Lildholdt et al15 in their study evaluated the 
number of persisting cultures after the end of treatment, 
which was also relevant for Goldenberg et al14 that is, whether 
and to what extent bacterial proliferation still existed after 
therapy was completed.
Adverse events
In the majority of the studies, adverse events were evaluated 
as an expression of safety. Four studies specified such events 
additionally13,16,17,19 by explicitly analyzing medication­
related adverse events; three studies evaluated clinical side 
effects/adverse events in general.12,14,18 Whether adverse 
events were of relevance in the study by Lildholdt et al 
remains unclear.
Timing of outcome assessment
The relevant point in time at which the primary and second­
ary outcome measures were assessed differed among the 
studies. Whereas in some studies the data were included in the 
analysis directly after the application phase was completed, 
others defined the time after a follow­up phase as decisive for 
the analysis. In only one case, the data from Day 3–4 formed 
the basis of the analysis.14
In the studies that conducted an analysis with data directly 
after treatment had ended, the point in time varied between 
Day 8 and Day 17. In the studies that collected data relevant 
to the target value after a follow­up phase, the time span 
ranged from Day 15 to Day 35.
Study results
Clinical cure
The included studies demonstrate the statistical equivalence 
between ciprofloxacin (0.2%) and the reference product 
PNH (Table 3). Some studies investigated the cure rate after 
completion of treatment.12,17,19 Here, the rate for patients 
whose condition fell into the category “clinical resolution” 
or “improvement” ranged between 93% and 100%. Studies 
that evaluated the outcome parameters after a follow­up 
period showed cure or improvement rates between 86.6% 
and 96.7%.13,15,18 Consequently, comparably high success 
rates for the ciprofloxacin 0.2% drug were determined in 
these studies.
Similar results were ascertained in the studies that inves­
tigated a higher concentration of ciprofloxacin (0.3%).14,16 In Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 4 Adverse events
Study ID Adverse events Medication-related AE Type and severity Premature  
discontinuation
Pistorius et al17 Group A: 66  
(23%)  
Group B: 70  
(25%)  
Group C: 55  
(20%)
Group A: 6%  
Group B: 5%  
Group C: 5%
Headache, ear pain,  
pruritus mainly mild or  
moderate in severity
Group A: 1  
Group B: 4  
Group C: 3
Arnes and Dibb12 None
Roland et al19 Group A: 6  
(5.7%)  
Group B: 5  
(5%)
Group A: 0  
Group B: 1  
(1.0%)
Mostly not serious  
(1 breast cancer)
11 (in most cases  
otitis media)
Drehobl et al13 Group A: 11  
(3.8%)  
Group B: 11  
(3.6%)
ear pruritus, headache,  
ear discomfort, application  
site pain/burning mostly  
of mild intensity
Group A: 3  
Group B: 3
Lildholdt et al15
Psifidis et al18 None
Goldenberg et al14 None
Marom et al16 Group A: 7  
(21%)  
Group B: 5  
(16%)
Group A: 4  
(12%) + 1 serious Ae  
Group B: 1 (3%)
Otalgia, tinnitus, pruritus,  
diarrhea, headache,  
throat pain
Group A: 1  
Group B: 0
Full texts
processed
N = 36 
Exclusion criteria: 
• No ciprofloxacin 
• Wrong concentration
of ciprofloxacin 
• Animal testing 
• No RCT 
Exclusion criteria: 
• No ciprofloxacin 
• Wrong concentration
of ciprofloxacin  
Results of the
database search
(abstracts read)
N = 38
Studies
relevant for the
review
N = 6
Studies relevant for the
review
(extension of the
inclusion criteria to
ciprofloxacin 0.3%)
N = 8
Figure 1 Flow chart.
the study by Goldenberg et al14 about 77% of patients who 
were treated with ciprofloxacin fulfilled the definition of cure 
on Day 3–4. After 14 days, the rate reached 100%. Marom 
et al16 found study participants in the per­protocol population 
to be 100% symptom­free at the end of a 7­day treatment 
phase. In the intent­to­treat population, complete resolution 
was observed in 93.6% of the patients in the ciprofloxacin 
group at the same point in time.
Microbial cure
The authors consistently identified high in vitro activity of 
ciprofloxacin against P . aeruginosa with high eradication 
rates of 83.3% to 95.7% and rare cases of persisting organ­
isms or superinfections (Table 3).
Psifidis et al18 and Pistorius et al17 who, besides cipro­
floxacin 0.2%, also tested a combination of ciprofloxacin 
0.2% and hydrocortisone 0.1%, observed that the addition of 
hydrocortisone raised the eradication rate even further.
In the treatment of patients who had an infection with 
S. aureus bacteria, ciprofloxacin proved effective in 72.7% 
of patients.
Adverse events
No adverse events occurred in some studies,12,18,19 but in oth­
ers, incidents that could be attributed to the medication took 
place at a rate of 3%–6% in the groups treated with cipro­
floxacin (Table 4). The majority of studies spoke exclusively 
of mild side­effects, with similar frequencies in the individual 
groups; premature discontinuation was rarely reported. 
Drehobl et al13 and Pistorius et al17 name headache, earache, 
and itching at the site of application as the main symptoms 
that could be linked to the trial medication.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Risk of bias
The greatest susceptibility to systematic distortions of the 
study results constituted the insufficient blinding of the 
included studies. While two study groups explicitly men­
tioned using non­blinding,16,18 four other authors made no 
comment whatsoever in this regard.12,14,15,18 Based on the fact 
that blinding was not addressed, however, it is to be assumed 
that blinding did not occur and the studies were open­label. In 
the study by Drehobl et al13 the evaluator at least was blinded, 
and only Roland et al19 conducted an observer/investigator­
blinded study.
In addition, the randomization procedure remained 
unclear in a large proportion of the studies. Although all 
were randomized, controlled studies according to the pub­
lications, the randomization process was mentioned in only 
three studies.12,16,19
Another deficit with reference to the included studies 
was the absence of two full texts. We could only draw on 
the information from the abstracts by Lildholdt et al15 and 
Psifidis et al18 because we were denied access to the complete, 
comprehensive material.
Discussion
The outcome measure “clinical success” consistently shows 
higher success rates in patients treated with the fluoro­
quinolone, than in the control groups. At the same time, 
the authors point out – in addition to the effectiveness of 
the active ingredient – the absence of any ototoxicity and the 
low systemic exposure caused by ciprofloxacin.
In summary, clinical equivalence can be determined 
for both of the treatment possibilities ciprofloxacin/ 
hydrocortisone and PNH plus amoxicillin in adults and 
children. However, low systemic exposure, the absence of 
ototoxicity, and the smaller dose speak clearly for treatment 
with ciprofloxacin.
Ciprofloxacin stands out due to its low rate of side effects. 
Adequate safety is thereby given with this fluoroquinolone.
For this reason, ciprofloxacin is not only non­inferior to 
other classes of antibiotics but also to antibiotic drugs that 
are combined with glucocorticoids.
Studies that evaluated microbiological activity come to 
the conclusion that the organism P . aeruginosa represents the 
main pathogen in the investigated population having acute 
otitis externa. The authors consistently ascertained high in 
vitro activity of ciprofloxacin against P . aeruginosa.
Special attention must be paid to patient compliance 
in the included studies. The lower the required application 
rate of the otologic drug, the more probable it is that the 
patients adhere to therapy and apply the medicine regularly. 
Thus we can   conclude that patients requiring fewer daily 
drug administrations will comply more closely with the 
  treatment plan.
When considering the bias, and consequently the results, 
we should pay particular attention to a certain distortion: 
due to the different daily application rates of the otologic 
drugs used, double­blinding of the study could not always 
be achieved.
The possibility of including a much larger number of 
  clinical studies in this review would have existed if the 
question at hand had also applied to ciprofloxacin 0.3% 
solution.
Other studies not included in this review combined cipro­
floxacin 0.2% solution with the glucosteroid dexamethasone, 
which can be categorized as a glucocorticoid belonging to 
the active substance class two to three analogous to the clas­
sification of therapeutic index of topical dermatotherapy, and 
is thus to be considered potent.20
These combination drugs were in turn tested against 
“conventional” combination drugs such as PNH. The efficacy 
of ciprofloxacin could be therefore increased.
Conclusion
The studies included in this review demonstrate the statistical 
equivalence of ciprofloxacin (0.2%) and the reference product 
PNH, and thereby confirm the hypothesis of non­inferiority 
in terms of the cure rate and microbiological eradication. 
The efficacy of ciprofloxacin 0.2% antibiotic ear solution 
can be acknowledged.
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